Compass Therapeutics Inc

For the period ended Dec 31, 2024. Filed Feb 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 27, 2025

CMPX$0.84+10.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except par value per share data)

	December 31,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$43,483	$24,228
Marketable securities	83,239	128,233
Prepaid expenses and other current assets	6,029	1,420
Total current assets	132,751	153,881
Property and equipment, net	353	898
Operating lease, right-of-use ("ROU") asset	6,731	1,776
Other assets	568	320
Total assets	$140,403	$156,875
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$2,249	$4,090
Accrued expenses	6,287	2,514
Operating lease obligations, current portion	338	1,197
Total current liabilities	8,874	7,801
Operating lease obligations, net of current portion	6,296	536
Total liabilities	15,170	8,337
Commitments and Contingencies (Note 11)
Stockholders' equity:
Common stock, $0.0001 par value: 300,000 shares authorized; 137,820 shares issued and outstanding at December 31, 2024; 127,668 shares issued and outstanding at December 31, 2023	14	13
Additional paid-in-capital	489,692	463,796
Accumulated other comprehensive income	210	37
Accumulated deficit	(364,683)	(315,308)
Total stockholders' equity	125,233	148,538
Total liabilities and stockholders' equity	$140,403	$156,875

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.